Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AXIOM: SBRT and Immunotherapy in Extracranial Melanoma Oligometastases
NCT06767306Phase 2Recruiting
- Sponsor
- Melanoma Institute Australia
- Start
- Mar 2025
- Primary completion
- Apr 2033
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial in melanoma (2 arms), sponsored by Melanoma Institute Australia. Primary endpoint: Overall survival at 5 years. Started Mar 2025; status: recruiting.
02
Conditions
melanoma
Beyond the preview
Go deeper on NCT06767306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06767306.